Inventage lab

What Inventage lab does

Inventage Lab (Inventagelab Inc.) is a South Korean clinical-stage biotechnology company founded in 2015 and publicly listed on KOSDAQ (ticker 389470) through the technology-growth special listing track in 2022. The company develops microfluidic-based drug delivery system (DDS) platforms, anchored by its proprietary Laminar-FLUIDigm™ laminar flow control system, organized into three product platforms: IVL-DrugFluidic® for long-acting injectable (LAI) microsphere formulations with dosing intervals of 1–6 months, IVL-BioFluidic™ for ultra-concentrated subcutaneous biologics, and IVL-GeneFluidic® for lipid nanoparticle (LNP) manufacture of mRNA and gene therapeutics. The company's pipeline spans veterinary products (notably the IVL2001 moxidectin-based 3-month heartworm prevention product launched in 2020), and human candidates across metabolic disease, CNS, dermatology, and rare disease indications including GLP-1 long-acting injectables with Yuhan, hair loss treatments with Daewoong, and peptide candidates with Boehringer Ingelheim.

The business model is a partnership-driven B2B platform licensing and co-development structure, with revenue generated from upfront and milestone payments on out-licensed pipelines, research and feasibility-study fees, and royalties on future product sales, supplemented by LNP CDMO services and HANDYGENE™ equipment sales through a joint commercialization agreement with EuBiologics. Inventage Lab holds granted patents covering microsphere manufacturing, LNP chips, sustained-release microparticles, and tissue repair compositions, and operates GMP manufacturing through its Seongnam-based IVL Manufacturing Center and the Quratis Bioplant facility in Osong, acquired via a 2025 majority equity stake in Quratis Co., Ltd. In March 2026, the company raised KRW 98.5 billion (~$66 million) in convertible securities to advance its platforms and expand manufacturing capacity.

Name

Inventage lab

Legal name

Inventagelab Inc.

Website

https://inventagelab.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

51–100 employees

Short description

Inventage Lab is a South Korean clinical-stage biotech that develops microfluidic drug delivery platforms — IVL-DrugFluidic, IVL-BioFluidic, and IVL-GeneFluidic — for long-acting injectables, biologics, and LNPs, licensing formulations and offering CDMO services to global pharmaceutical and veterinary companies.

Ownership category

akta.pro rank

Product category

Drug Delivery Systems / Pharmaceutical Technology Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

mRNA/LNP & Nucleic Acid Therapeutics CDMO (HLAGABAF)

akta.pro secondary industries

Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH), Drug Substance–Drug Product Integrated CDMO (HLAGABAG), mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA) (HLAGAGAC), Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)

Keywords

• Microfluidic drug delivery
• Long-acting injectables
• Lipid nanoparticle manufacturing
• Biopharmaceutical formulation
• CDMO services

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Marketing or Sales, Operations, Supply Chain

Revenue model

1. Platform Licensing and Out-licensing: Inventage Lab out-licenses differentiated formulation pipelines developed on its DrugFluidic platform to global pharmaceutical companies. Revenue is generated through upfront payments, milestone payments tied to development and regulatory achievements, and royalties on product sales.
2. Joint Research and Co-development: Collaborative research model applying DrugFluidic or BioFluidic platforms to partner APIs. Revenue generated through research fees, feasibility study payments, and development milestone payments across phased collaboration stages.
3. LNP CDMO Services: Contract development and manufacturing services for LNP (Lipid Nanoparticle) products based on the IVL-GeneFluidic platform. Includes HANDYGENE equipment sales and GMP-level production services through partnership with EuBiologics.
4. Equity and Funding Capital: The company raised ₩98.5 billion (approximately $66 million) through convertible preferred shares, convertible bonds, and bonds with warrants from investors including Flexus Partners, Timefolio Asset Management, and Stonebridge Ventures.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels7 records

Core offering

Inventage Lab develops and licenses microfluidic-based drug delivery system (DDS) platforms (IVL-DrugFluidic®, IVL-BioFluidic™, IVL-GeneFluidic®) that enable long-acting injectable, high-concentration subcutaneous biologic, and LNP-based nucleic acid formulations for pharmaceutical partners. The company also operates a pipeline of in-house drug candidates, sells HANDYGENE™ LNP manufacturing equipment, and provides LNP CDMO services for mRNA and gene therapy clients.

Product overview

Inventage Lab is a clinical-stage biotech company that has developed a portfolio of proprietary microfluidic-based drug delivery system (DDS) platforms. The core product architecture consists of three technology platforms: IVL-DrugFluidic® for long-acting injectable formulations producing ultra-uniform microspheres, IVL-BioFluidic™ for high-concentration subcutaneous biologics formulations, and IVL-GeneFluidic® for LNP-based nucleic acid delivery. These platforms are underpinned by the proprietary Laminar-FLUIDigm™ microfluidic system and supported by HANDYGENE™ manufacturing equipment. The company operates a pipeline of in-house developed drug candidates across veterinary and human applications spanning multiple therapeutic areas (metabolic diseases, CNS, dermatology, rare diseases), and offers CDMO manufacturing services. Manufacturing capabilities include the IVL Research Center and QuratisBioplant GMP facility.

Differentiator

Problem solved

Functional benefit

Brands

• IVL-DrugFluidic®: Microfluidic long-acting injectable (LAI) platform producing ultra-uniform microspheres for precise, tunable, and predictable drug release.
• IVL-BioFluidic™
• IVL-GeneFluidic®
• Laminar-FLUIDigm™
• HANDYGENE™
• QuratisBioplant
• IVL Research Center (IRC)

Products and services

• IVL-DrugFluidic®

Quantifiable outcome

• Dosing frequency reduced from 52 weekly injections to 12 annual injections in obesity treatments
• +3 more outcomes

Named customers10 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eleven partnerships are on record, tiered core and minor.

• Boehringer Ingelheim Pharmaceuticals Inc.coreStrategic or Co-development Partner · 1 January 2025Joint research and development agreement for long-acting injectable formulation of a peptide candidate (IVL5006 at preclinical stage, IVL5007 at formulation stage) for undisclosed indication. This is a high-profile partnership with a top-10 global pharmaceutical company for novel peptide therapeutics.
• EuBiologics Co., Ltd.coreTechnology or Integration · 1 January 2025Joint LNP CDMO commercialization contract for GMP-level production based on IVL-GeneFluidic platform. Partnership enables scaled manufacturing capabilities for mRNA and gene therapy clients.
• Quratis Co., Ltd.coreTechnology or Integration · 1 January 2025Acquisition of Quratis Co., Ltd. through equity participation making Inventage Lab the largest shareholder. Construction agreement for long-acting injectable manufacturing facility at Quratis Bioplant in Osong. Investment in expanding GMP manufacturing capacity.
• Daewoong PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2025Co-development and exclusive technology licensing for hair loss treatment (IVL3001, finasteride-based 1-month sustained-release injectable for male pattern hair loss). Daewoong also developing long-acting semaglutide for obesity through separate collaboration.
• Chong Kun DangminorStrategic or Co-development Partner · 1 January 2025Partner for IVL3003 (donepezil-based 1-month sustained-release injectable for dementia treatment in clinical development).
• VirbaccoreStrategic or Co-development Partner · 1 January 2025Partner for veterinary heartworm prevention products including IVL2002 and IVL2004 (6-month and 12-month moxidectin formulations) and IVL2003/5 (deslorelin-based chemical castration products). Next-generation veterinary product development.
• CKD PharmminorChannel Partner/ Reseller/ Distributor · 1 January 2025Listed as a partner company on Inventage Lab's partnering page.
• Yuhan CorporationcoreStrategic or Co-development Partner · 1 January 2024Co-development and commercialization agreement for long-acting injectable formulations of GLP-1 compounds including semaglutide (IVL3021) and tirzepatide (IVL3024) targeting diabetes and obesity treatment. Also partnership on CBD-based epilepsy treatment (IVL5005).
• Withus PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2024Exclusive license-out agreement for IVL3013 (dutasteride-based 3-month sustained-release injectable for benign prostatic hyperplasia). Receipt of KRW 500 million milestone payment. Also CMO partnering for hair loss treatment (IVL3001, IVL3002).
• ST Pharm Co., Ltd.minorStrategic or Co-development Partner · 1 January 2022Co-development agreement for IVL5002, a novel AIDS therapeutic candidate.
• NotuscoreStrategic or Co-development Partner · 1 January 2021Exclusive sales and business partnership for 3-month and 6-month sustained-release heartworm prevention products (IVL2001, IVL2002). Exclusive license-out for veterinary dementia therapeutics (IVL2007, IVL2008).

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Genevant Sciences: LNP-based nucleic acid delivery platform company focused on RNA therapeutics. Directly comparable in lipid nanoparticle drug delivery technology and serves overlapping biotech customers developing mRNA and gene therapeutics.
• Evonik Health Care: Specialty pharmaceutical CDMO with strong long-acting injectable capabilities (including biodegradable polymers and RESOMER®). Directly comparable in microfluidic-controlled sustained-release formulation, serving similar pharmaceutical and veterinary customers globally.
• Nanomi: Dutch specialist in microfluidic encapsulation technologies for drug delivery and diagnostics, with monodisperse microsphere production using techniques comparable to Inventage Lab's Laminar-FLUIDigm™. A close pure-play peer in microfluidic DDS technology.
• Acuitas Therapeutics: Canadian specialist in lipid nanoparticle delivery technology for mRNA therapeutics, supplying partners including Pfizer/BioNTech. Most directly comparable peer for Inventage Lab's IVL-GeneFluidic LNP CDMO business and microfluidic nucleic acid delivery platform.
• Kindeva Drug Delivery: Global CDMO specializing in drug delivery and combination products including complex injectables and inhalation. Comparable in sustained-release injectable formulation CDMO services and serves similar large pharma customers globally.

Regional players

• Samsung Biologics: Korea's largest biopharmaceutical CDMO with global biologics manufacturing capacity. A natural regional comparable given shared geography, similar pharma customers in Asia, and overlapping biologics formulation capabilities.
• Bora Pharmaceuticals: Taiwanese-headquartered CDMO with significant oral and injectable manufacturing capabilities across Asia-Pacific. Comparable as a regional peer with similar pharmaceutical formulation focus and Korean/Asian pharma customer base.

Broad incumbents

• Lonza: One of the world's largest CDMOs with leading capabilities in biologics manufacturing, mRNA/LNP services, and parenteral delivery. Comparable through its IVL-GeneFluidic-overlapping LNP CDMO business and biologic fill-finish offerings.
• West Pharmaceutical Services: Global leader in injectable drug delivery components and devices for biologics and small molecules. Overlaps with Inventage Lab's IVL-BioFluidic subcutaneous delivery focus and serves many of the same large pharma customers.
• Catalent: Major global CDMO with extensive sterile injectable, biologics, and oral dose capabilities. Comparable as a broad-spectrum drug delivery CDMO serving similar pharma customers, though with much wider scale and modality coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/inventage-lab
• Facebookfacebook.com/lab.inventage.9

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds2 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inventage lab